乳腺癌,癌转移抑制基因 z-bo 2020-10-20 377

　　Recently, researchers at Boston University School of Medicine (BUSM) discovered genes that play a role in the development of breast cancer in metastatic disease. This may help predict the progression of the disease and serve as a target for future breast cancer treatment. Researchers have identified a gene called serum deficiency response (SDPR) and the mechanism by which this gene is down-regulated or silenced in breast cancer cells that promote tumor spread.

　　Using the breast cancer progression model, researchers found that invasive and metastatic breast cancer cells have almost no SDPR gene expression. In addition, when the gene is overexpressed (or turned on) in a metastatic breast cancer cell model, the incidence of metastatic disease is significantly reduced. With the advent of advanced technologies, genomic research has discovered new genes that inhibit tumor metastasis (such as SDPR), which can prevent breast cancer from spreading to far places. In this study, BUSM researchers elaborated on the work in this field, and they are mainly about the regulation of epigenetic mechanisms. Current research is genetic regulation through epigenetic mechanisms (rather than genetic mechanisms), so that cancer cells can easily adapt to the microenvironment of new human organs far away from the initial site of cancer cells.

　　According to the researchers, this study is very important because the metastatic spread of breast cancer cells is a serious clinical obstacle to curative treatment. The spread of cancer is the death of breast cancer and other cancer patients. main reason. Sam Thiagaringham, associate professor of medicine, genetics, genomics, pathology, and experimental medicine at Boston University School of Medicine explained: “This is very important for understanding the underlying molecular mechanisms that promote/prevent cancer metastasis.”

　　Based on published data (bladder cancer, colon cancer, resection is not limited to breast cancer, because tumor samples from lung cancer, pancreatic cancer, ovarian cancer, and sarcoma also show loss of SDPR expression. Its function as a metastasis inhibitor can affect many Kind of cancer.

　　Thiagalingam added: "This is a major advance in understanding the molecular basis of metastatic disease. It may help predict the progression of metastatic cancer, but it has potential importance in the development of precise cancer treatments in the future. Gender must The drug targets controlled by SDPR have been confirmed."